Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia (WM).

被引：0
|
作者：
Lasica, Masa
Ailawadhi, Sikander
Fu, Chengcheng
Thomas, Sheeba K.
Wu, Depei
Yi, Shuhua
Siddiqi, Tanya
Yin, Qingsong
Allan, John N.
Chen, Wenming
Matous, Jeffrey V.
Feng, Ru
Chen, Zi
Yu, Min
Li, Mingyu
He, Zicong
Ahmad, Mohammad
Wang, Hengbang
Chanan-Khan, Asher Alban Akmal
Zhai, Yifan
机构：
[1] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[2] Mayo Clin Florida, Jacksonville, FL USA
[3] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
[6] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Weill Cornell Med, New York, NY USA
[9] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[10] Colorado Blood Canc Inst, Denver, CO USA
[11] Sarah Cannon Res Inst, Denver, CO USA
[12] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[13] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[14] Ascentage Pharma Grp Inc, Rockville, MD USA
[15] Ascentage Pharma Pty Ltd, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7078
引用
收藏
页数：1
相关论文
共 28 条
  • [21] BCL-2 inhibitor APG-2575 promotes anti-tumor efficacy of immune checkpoint blockade through converting tumor-associated macrophages into M1 phenotype in non-small cell lung cancer.
    Luo, Fan
    Lu, Fei Teng
    Qiu, Miao Zhen
    Pan, Wen Tao
    Zhang, Lin
    Zhao, Hong Yun
    Zhang, Li
    Yang, Da Jun
    CANCER RESEARCH, 2021, 81 (13)
  • [22] A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstrom Macroglobulinemia (WM): Preliminary Data
    Soumerai, Jacob D.
    Lasica, Masa
    Opat, Stephen
    Cheah, Chan Y.
    Chan, Henry
    Verner, Emma
    Barca, Eva Gonzalez
    Tedeschi, Alessandra
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    BLOOD, 2022, 140 : 9325 - 9327
  • [23] Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study
    de Vos, Sven
    Leonard, John P.
    Friedberg, Jonathan W.
    Zain, Jasmine
    Dunleavy, Kieron
    Humerickhouse, Rod
    Hayslip, John
    Pesko, John
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 810 - 818
  • [24] The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study
    Ghobrial, Irene M.
    Siegel, David
    Vij, Ravi
    Wolf, Jeffrey L.
    Berdeja, Jesus G.
    Matous, Jeffrey V.
    Lipman, Peter
    Patel, Chirag
    Le, Trinh
    Rommel, Christian
    Berk, Gregory
    BLOOD, 2012, 120 (21)
  • [26] Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    De Vos, Sven
    Flowers, Christopher
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan Hale
    Reid, Erin G.
    Cordero, Jaclyn
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Salem, Ahmed H.
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma
    Weber, Jeffrey S.
    Flaherty, Keith T.
    Infante, Jeffrey R.
    Falchook, Gerald Steven
    Kefford, Richard
    Daud, Adil
    Hamid, Omid
    Gonzalez, Rene
    Kudchadkar, Ragini Reiney
    Lawrence, Donald P.
    Burris, Howard A.
    Long, Georgina V.
    Algazi, Alain Patrick
    Lewis, Karl D.
    Kim, Kevin B.
    Puzanov, Igor
    Sun, Peng
    Little, Shonda M.
    Patel, Kiran
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.
    Baird, Richard D.
    Van Rossum, Annelot
    Oliveira, Mafalda
    Beelen, Karin
    Garcia-Corbacho, Javier
    Mandjes, Ingrid A. M.
    Vallier, Anne-Laure
    van Werkhoven, Erik D.
    Kumar, Sanjeev Srinivas
    van Tinteren, Harm
    Beddowes, Emma
    Rosing, Hilde
    Schrier, Mariette
    Schultink, Aurelia de Vries
    Saura, Cristina
    Bernards, Rene
    Tabernero, Josep
    Cortes, Javier
    Caldas, Carlos
    Linn, Sabine C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
123